Apotex fails to block FDA import ban with NAFTA; Iroko nabs osteoarthritis approval for Zorvolex;

@FiercePharma: Top-read on FierceAnimalHealth Monday: Merck releases tilapia vaccine. Article | Follow @FiercePharma

@EricPFierce: Boehringer Ingelheim opens a $30M packaging plant for its Vetmedica animal health biz. FierceAnimalHealth story | Follow @EricPFierce

@CarlyHFierce: Great news for those who have always wanted to hear me moderate a webinar: You're getting another chance. Register | Follow @CarlyHFierce

> Canada-based Apotex failed to persuade arbitrators that the FDA violated the North American Free Trade Agreement when it barred imports from two of the company's plants in Ontario. Release

> Philadelphia-based Iroko Pharmaceuticals won FDA approval for a new use for its nonsteroidal anti-inflammatory drug, Zorvolex, for osteoarthritis pain. Release

> Vivus ($VVUS), which sells the weight loss drug Qsymia, bought patents covering one of the drug's ingredients, topiramate, from Johnson & Johnson's ($JNJ) Janssen unit. Report

> India's Torrent Pharmaceuticals won exemptions from domestic price controls for two of its drugs, sending its shares soaring. Report

> Merck ($MRK) signed up for a training program to teach its employees to save energy. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Chinese physicians implant first 3-D printed vertebrae in child. Article | Follow @FierceMedDev

@VarunSaxena2: RT @FierceMedicalDevices: FDA simplifies approval process for innovative devices lacking a predecessor. Story | Follow @VarunSaxena2

@EmilyWFierce: Richard III was a foodie, according to a recent chemical analysis of the medieval king's teeth. NYT story | Follow @EmilyWFierce

> Researchers develop implant/app combo to monitor glaucoma in aging eyes. Story

> Philips Lifeline adds emergency response app to its service. Article

> Medtronic snags FDA approval for next-generation pacemaker. Report

Biotech News

@FierceBiotech: Banking on its R&D rep, Calithera looks to raise $80M in IPO. News | Follow @FierceBiotech

@JohnCFierce: Kite Pharma soars on early evidence that CAR-T treatment quells cancer. Report | Follow @JohnCFierce

@EmilyMFierce: Cubist exec: Challenges mount in antibiotics discovery. FierceBiotech Research report | Follow @EmilyMFierce

> Pfizer and Merck extend heavyweight immuno-oncology pact to lung cancer. More

> Civitas nails $55M venture round for a PhIII Parkinson's study. Story

> Alkermes closer to launching once-monthly schizophrenia drug into a crowded market. Article

Biotech Research News

> Cubist exec: Challenges mount in antibiotics discovery. Editor's Corner

> Tuberculosis biomarker predicts protection against disease symptoms. Article

> Scientists engineer opiate pain medicine without using poppies. Story

> Thymus gland grown from reprogrammed cells in lab. More

> Study: Early barriers in drug development are widespread. Report

Pharma Manufacturing News

> Sources: Ranbaxy's manufacturing problems lead to Texas. News

> Lupin took hard look at troubled Wockhardt for possible bid. More

> Alexion gets new Form 483 in follow-up inspection. Article

> Lonza looks to biotech funders for entree to business. Story

> Teva recalls Parkinson's disease drug because it may be 'superpotent.' Report

> PSC buys high-potency fill-finish facility from U.S. research group. Item

And Finally... Cancer survival rates are rising in the U.K., according to a government study. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.